{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:29:32Z","timestamp":1771626572699,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":3681,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>This study used intravital microscopy to investigate the receptors stimulated by amylin which shares around 50% sequence homology with the vasodilator calcitonin gene\u2010related peptide (CGRP) in the hamster cheek pouch microvasculature <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Receptor agonists dilated arterioles (diameters 20\u201340\u2003\u03bcm). The \u2212log of the concentrations (\u00b1s.e.mean; <jats:italic>n<\/jats:italic>=8) causing 50% increase in arteriole diameter were: human \u03b2CGRP (10.8\u00b10.3), human \u03b1CGRP (10.8\u00b10.4), rat \u03b1CGRP (10.4\u00b10.3). Rat amylin and the CGRP<jats:sub>2<\/jats:sub> receptor selective agonist [Cys(ACM<jats:sup>2,7<\/jats:sup>]\u2010human \u03b1CGRP were 100 fold less potent (estimates were 8.5\u00b10.4 and 8.2\u00b10.3 respectively).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The GCRP<jats:sub>1<\/jats:sub> receptor antagonist, CGRP<jats:sub>8\u201337<\/jats:sub> (300\u2003nmol\u2003kg<jats:sup>\u22121<\/jats:sup>; i.v.) reversibly inhibited the increase in diameter evoked by human \u03b1CGRP (0.3\u2003n<jats:sc>M<\/jats:sc>) from 178\u00b122% to 59\u00b112% (<jats:italic>n<\/jats:italic>=8; <jats:italic>P<\/jats:italic>&lt;0.05) and by rat amylin (100\u2003n<jats:sc>M<\/jats:sc>) from 138\u00b123% to 68\u00b124% (<jats:italic>n<\/jats:italic>=6; <jats:italic>P<\/jats:italic>&lt;0.05). CGRP<jats:sub>8\u201337<\/jats:sub> did not inhibit vasodilation evoked by substance\u2003P (10\u2003n<jats:sc>M<\/jats:sc>; <jats:italic>n<\/jats:italic>=4; <jats:italic>P<\/jats:italic>&gt;0.05).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The amylin receptor antagonist, amylin<jats:sub>8\u201337<\/jats:sub> (300\u2003nmol\u2003kg<jats:sup>\u22121<\/jats:sup>; i.v.) did not significantly inhibit the increase in diameter evoked by human \u03b1CGRP (0.3\u2003n<jats:sc>M<\/jats:sc>) which was 112\u00b126% in the absence, and 90\u00b129% in the presence of antagonist (<jats:italic>n<\/jats:italic>=4; <jats:italic>P<\/jats:italic>&lt;0.05); nor that evoked by rat amylin (100\u2003n<jats:sc>M<\/jats:sc>) which was 146\u00b123% in the absence and 144\u00b132% in the presence of antagonist (<jats:italic>n<\/jats:italic>=4; <jats:italic>P<\/jats:italic>&gt;0.05).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The agonist profile for vasodilatation and the inhibition of this dilatation by CGRP<jats:sub>8\u201337<\/jats:sub>, although not the amylin<jats:sub>8\u201337<\/jats:sub> indicates that amylin causes vasodilatation through interaction with CGRP<jats:sub>1<\/jats:sub> receptors in the hamster cheek pouch.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (1999) <jats:bold>126<\/jats:bold>, 280\u2013284; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0702272\">10.1038\/sj.bjp.0702272<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0702272","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T19:54:15Z","timestamp":1106942055000},"page":"280-284","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Interaction of amylin with calcitonin gene\u2010related peptide receptors in the microvasculature of the hamster cheek pouch <i>in vivo<\/i>"],"prefix":"10.1111","volume":"126","author":[{"given":"Judith M","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan D","family":"Brain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.65031131.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1995.103"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1139\/y95-144"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/313054a0"},{"key":"e_1_2_7_6_1","first-page":"3","article-title":"Amylin\/islet amyloid polypeptide: biochemistry, physiology, pathophysiology","volume":"21","author":"CASTILLO M.J.","year":"1995","journal-title":"Diabetes & Metabolisme"},{"key":"e_1_2_7_7_1","first-page":"989","article-title":"Vasodilator responses to calcitonin gene\u2010related peptide (CGRP) and amylin in the rat isolated perfused kidney are mediated via CGRP1 receptors","volume":"269","author":"CHIN S.Y.","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_8_1","first-page":"1226","article-title":"Nonadrenergic and noncholinergic arterial dilatation and venoconstriction are mediated by calcitonin gene\u2010related peptide1 and neurokinin\u20101 receptors, respectively, in the mesenteric vasculature of the rat after perivascular nerve stimulation","volume":"263","author":"CLAING A.","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)81389-0"},{"key":"e_1_2_7_10_1","first-page":"123","article-title":"hCGRP8\u201337, a calcitonin gene\u2010related peptide antagonist revealing calcitonin gene\u2010related peptide receptor heterogeneity in brain and periphery","volume":"254","author":"DENNIS T.","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_11_1","first-page":"718","article-title":"Structure\u2010activity profile of calcitonin gene\u2010related peptide in peripheral and brain tissues. Evidence for receptor multiplicity","volume":"251","author":"DENNIS T.","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-2862(73)90059-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13878.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb12775.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4179(93)90175-A"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb17020.x"},{"key":"e_1_2_7_17_1","first-page":"101","volume-title":"Neurogenic Inflammation","author":"HALL J.M.","year":"1996"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb17180.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(98)01234-6"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(88)90064-4"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/30666"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1139\/y95-133"},{"key":"e_1_2_7_23_1","first-page":"7625","article-title":"Islet amyloid polypeptide (amylin) is expressed in sensory neurons","volume":"15","author":"MULDER H.","year":"1995","journal-title":"J. Neurochem."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(97)00178-2"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(92)90036-Y"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)89093-8"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701760"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb16737.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90036-1"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00544-4"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.42.2.330"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701783"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0702272","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0702272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0702272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T22:32:55Z","timestamp":1698532375000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0702272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1038\/sj.bjp.0702272"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0702272","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}